Blood cancer could be the leading form of cancer deaths by 2035, according to Australia's first strategic action plan.
Acute myeloid leukemia is the deadliest form of blood cancer with a high rate of treatment failure and relapse. Relapsed leukemia has an extremely poor survival of <10%.
Chemotherapy is the first-line treatment for the deadly blood cancer. However, it is not effective against dormant (inactive) malignant stem cells that consequently regenerate a more aggressive leukemia using their unique tumorigenic/stemness characteristics. Ablating leukemia stem cells is critical for successful anticancer therapy.
Over the past 9 years, our lab has generated a body of knowledge in the discovery of therapeutic targets essential for leukemia stem cell characteristics and established evidence of therapeutic efficacy for clinical trials. Most of our research has been published in top scientific journals including Cancer Cell and Blood.
In partnership with industry and close collaboration with clinicians, we are currently converting our research breakthroughs into innovative stem cell-targeted therapies in clinical trials, which will directly benefit patients with the deadly blood cancer.